Literature DB >> 17710443

Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis.

Nicolas Penel1, Sylvain Dewas, Philippe Doutrelant, Stéphanie Clisant, Yazdan Yazdanpanah, Antoine Adenis.   

Abstract

BACKGROUND: Cancer-associated hypercalcemia (CAH) is the most frequent metabolic disorder in cancer patients. We retrospectively reviewed the outcome and prognostic factors for patients with CAH being treated with standard intravenous disphosphonates.
MATERIALS AND METHODS: Two hundred sixty patients were reviewed. Overall survival and prognostic factors were analyzed. Relative risks (RR) for early death (within 60 days) were assessed (Fischer exact test and logistic regression model).
RESULTS: Median survival was 64 days (range, 12-1,955+). Multivariate analysis identified the following factors as poor survival predictors: serum corrected calcium >2.83 mmol/l [hazard ratio (HR) = HR 2.21], albuminemia <35.5 (HR 2.41), squamous cell carcinoma (HR 2.64), bone metastasis (HR 1.44), and liver metastasis (HR 2..22). One hundred twenty-one patients died within 60 days. For those patients, the logistic regression model identified four independent predicting factors for early death: calcemia >2.83 mmol/l (RR 5.07), hypoalbuminemia (RR 7.42), liver metastasis (RR 4.34), and squamous cell carcinomas (RR 2.21). DISCUSSION: Despite intravenous diphosphonate, CAH is still associated with poor outcome. Simple bedside parameters may estimate the risk of early deaths.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17710443     DOI: 10.1007/s00520-007-0322-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  25 in total

1.  Prognosis of hypercalcemia in aerodigestive tract cancers: study of 136 recent cases.

Authors:  Nicolas Penel; Céline Berthon; Frédéric Everard; Jean-Charles Neu; Stéphanie Clisant; Michèle N'guyen; Stéphanie Villet; Charles Fournier; Jean-Louis Lefebvre
Journal:  Oral Oncol       Date:  2005-10       Impact factor: 5.337

2.  Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party.

Authors:  Bradley M Augustson; Gulnaz Begum; Janet A Dunn; Nicola J Barth; Faith Davies; Gareth Morgan; Judith Behrens; Alastair Smith; J Anthony Child; Mark T Drayson
Journal:  J Clin Oncol       Date:  2005-11-07       Impact factor: 44.544

3.  Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.

Authors:  J J Body; A Borkowski; A Cleeren; O L Bijvoet
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

4.  Hypercalcemia of cancer in the digestive tract.

Authors:  S Monno; A Nagata; S Furuta
Journal:  J Clin Gastroenterol       Date:  1987-02       Impact factor: 3.062

5.  Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.

Authors:  H Gurney; V Grill; T J Martin
Journal:  Lancet       Date:  1993-06-26       Impact factor: 79.321

6.  Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.

Authors:  S R Nussbaum; J Younger; C J Vandepol; R F Gagel; M A Zubler; R Chapman; I C Henderson; L E Mallette
Journal:  Am J Med       Date:  1993-09       Impact factor: 4.965

7.  Hypercalcemia in patients with breast cancer: a survival study.

Authors:  S de Wit; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 8.  Tumor hypercalcemia and "ectopic hyperparathyroidism".

Authors:  P Skrabanek; J McPartlin; D Powell
Journal:  Medicine (Baltimore)       Date:  1980-07       Impact factor: 1.889

9.  Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).

Authors:  P J Ling; R P A'Hern; J R Hardy
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

10.  Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.

Authors:  J Walls; W A Ratcliffe; A Howell; N J Bundred
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

View more
  8 in total

1.  An osteoclast-targeting agent for imaging and therapy of bone metastasis.

Authors:  Wei Liu; Asghar Hajibeigi; Mai Lin; Cynthia L Rostollan; Zoltan Kovacs; Orhan K Oz; Xiankai Sun
Journal:  Bioorg Med Chem Lett       Date:  2008-07-27       Impact factor: 2.823

2.  Cancer-associated hypercalcemia: validation of a bedside prognostic score.

Authors:  Nicolas Penel; Sylvain Dewas; Aurélien Hoffman; Antoine Adenis
Journal:  Support Care Cancer       Date:  2009-03-17       Impact factor: 3.603

3.  Hypercalcemia.

Authors:  Gary R Wolch
Journal:  Can Fam Physician       Date:  2008-09       Impact factor: 3.275

4.  Development of a score that predicts survival among patients with bone metastasis revealing solid tumor.

Authors:  Nicolas Penel; Antoine Hollebecque; Carlos Maynou; Jérôme Dewaele; Marie Jasserand; Régis Beuscart; Marie-Hélène Vieillard
Journal:  Support Care Cancer       Date:  2008-05-14       Impact factor: 3.603

5.  Malignancy associated hypercalcaemia-responsiveness to IV bisphosphonates and prognosis in a palliative population.

Authors:  Shreyashee Mallik; Girijasankar Mallik; Shireen Teves Macabulos; Andrew Dorigo
Journal:  Support Care Cancer       Date:  2015-10-06       Impact factor: 3.603

6.  Clinical Characteristics, Causes and Survival in 115 Cancer Patients with Parathyroid Hormone Related Protein-mediated Hypercalcemia.

Authors:  Joon Jin; Jin Ook Chung; Min Young Chung; Dong Hyeok Cho; Dong Jin Chung
Journal:  J Bone Metab       Date:  2017-11-30

7.  Inpatient management of hypercalcemia portends a poor prognosis among gynecologic oncology patients: A trigger to initiate hospice care?

Authors:  James C Cripe; Tommy R Buchanan; Leping Wan; Andrea R Hagemann; Carolyn K McCourt; L Stewart Massad; Katherine C Fuh; David G Mutch; Mathew A Powell; Premal H Thaker; Lindsay M Kuroki
Journal:  Gynecol Oncol Rep       Date:  2019-01-26

8.  Malignancy-Related Hypercalcemia in Advanced Solid Tumors: Survival Outcomes.

Authors:  Ricardo Emanuel de Oliveira Ramos; Milena Perez Mak; Michel Fabiano Silva Alves; Gustavo Henrique Munhoz Piotto; Tiago Kenji Takahashi; Leonardo Gomes da Fonseca; Marina Cavalcanti Maroja Silvino; Paulo Marcelo Hoff; Gilberto de Castro
Journal:  J Glob Oncol       Date:  2017-03-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.